NY-GOLDEN-FALCON-ACQ
Golden Falcon Acquisition Corp. (NYSE:GFX.U ) (the “Company ”) announced today that the underwriters of its previously announced initial public offering have exercised their over-allotment option in full, which will result in the issuance of an additional 4,500,000 units at a public offering price of $10.00 per unit. After giving effect to the exercise and close of the over-allotment option, an aggregate of 34,500,000 units will be issued in the initial public offering and an aggregate of $345 million will be deposited in the Company’s trust account at the closing of the offering, which is expected to occur on December 22, 2020.
Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on the NYSE under the symbols “GFX ” and “GFX WS ” respectively.
The Company, led by Makram Azar and Scott Freidheim, was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. While the Company may pursue an initial business combination with any target business and in any sector or geographical location, it intends to focus its search on companies operating in the technology, media, telecommunications and fintech sectors that are headquartered in Europe, Israel, the Middle East or North America.
UBS Securities LLC and Moelis & Company LLC are acting as joint book-running managers of this offering and EarlyBirdCapital, Inc. as lead manager for the offering. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from UBS Securities LLC, Attn: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone at (888) 827-7275, or by e-mail at olprospectusrequest@ubs.com .
A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC ”) and became effective on December 17, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Golden Falcon Acquisition Corp.
The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganisation or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies in the technology, media, telecommunications and fintech sectors that are headquartered in Europe, Israel, the Middle East or North America. The Company is led by Chief Executive Officer, Makram Azar, and Chairman, Scott Freidheim.
FORWARD-LOOKING STATEMENTS
This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds thereof. No assurance can be given that the offering discussed above will be completed on the terms described, or at all , or that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov . The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005726/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First in Human Ischemic VT Ablation Successfully Performed in iCMR5.11.2025 16:55:00 CET | Press release
Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first Ischemic Ventricular Tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105120761/en/ Imricor’s NorthStar® Mapping System The Amsterdam UMC team, shown here, performed the VT ablation procedure following previous experiences performing atrial flutter and premature ventricular complex (PVC) ablation procedures guided by real-time MRI and Imricor’s NorthStar® Mapping System. Regarding the VT procedure, Dr. Kemme, stated: “This procedure is part of an international research programme. The MRI imaging shows us precisely where the myocardial infarction took place; therefore, we can send the catheter to the exact spot. This information can make ablation possi
SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified Lesions5.11.2025 16:12:00 CET | Press release
SIS Medical AG, a Swiss manufacturer of the Super-High-Pressure PTCA balloon catheter (OPN NC), is pleased to announce that the results of the investigator-initiated VICTORY trial were presented during the late-breaking clinical session at TCT 2025 by the Cardiovascular Research Foundation (CRF). The randomized, multi-center clinical study was designed to compare the safety and efficacy between the OPN and IVL devices for lesion preparation and optimized stent expansion in highly complex calcified coronary lesions, deploying a drug-eluting stent (DES). Coronary artery calcium affects approximately one-third of patients undergoing PCI and is a key contributor to procedural and stent failure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105812157/en/ "With a similar safety profile, OPN can be a feasible and faster alternative to IVL." Dr. M. Bossard, Senior Physician at Luzerner Kantonsspital, Switzerland A total of 282 p
Doha Debates Explores the Role of Ancient Wisdom in Today’s World5.11.2025 16:06:00 CET | Press release
Experts and students debate whether ancient wisdom holds answers for modern societies As the world grapples with questions of meaning and moral direction, Doha Debates takes on a fundamental question: Should ancient wisdom guide today’s societies? This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105183709/en/ Guest speakers and participating students gather on the Doha Debates stage to discuss a fundamental question “Should ancient wisdom guide today’s societies?” — part of the show’s exploration of timeless questions shaping our world today. (Photo: AETOSWire) In this episode of the new flagship season, moderated by Dareen Abughaida, students from across Qatar join three global thinkers to wrestle with a timeless dilemma: whether the answers to our most pressing problems lie in tradition or in bold new ideas. Wael Hallaq, Avalon Foundation Professor in the Humanities at Columbia University, critiques what he calls the “mor
Versa Delivers Proven Firewall Performance and Security Effectiveness Validated by Independent Testing5.11.2025 15:30:00 CET | Press release
Versa One of Only Three Recommended Products, Maintaining Position as Performance Leader by Delivering Fastest Throughput While Achieving a 99.43% Security Effectiveness Score Versa, the global leader in unified networking and security, today announced that its Next-Generation Firewall received CyberRatings.org’s highest “Recommended” rating for the ninth consecutive year. In the newly published Q3 2025 Enterprise Firewall report, based on independent testing by NSS Labs, Versa delivered 100% scores in critical categories like malware and exploit evasion resistance, and achieved a leading 7,626 Mbps rated throughput, over twice as fast as competing solutions. Selecting cybersecurity solutions requires unbiased, real-world performance testing and evaluation. CyberRatings.org provides IT and security leaders with data-driven results to guide investment decisions. In this latest assessment, Versa ranked among the top three vendors for Security Effectiveness and delivered more than twice t
Its Global Vision on Show, TVS Motor Company Makes a Stellar Debut at EICMA5.11.2025 15:16:00 CET | Press release
Six new products - a resurgent “new Norton”, connected technology, AR based Heads-Up Display Helmets, new range of accessories and a roadmap for Europe - underline TVSM’s presence at the world’s largest 2-wheeler exhibition. TVS Motor Company (TVSM) - a global leader in two and three-wheeler manufacturing - has taken centerstage at EICMA 2025, making a landmark debut at the world’s largest motorcycle exhibition. With a show floor commanding presence, TVS unveiled 6 new products across ICE and thermal powertrains, advanced ride assist gear including AR based Heads-Up display helmets, a stunning new range of accessories, connected technology that enhances rider-machine connect and its roadmap for expansion in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105242034/en/ TVS top leadership team posing with the global showcases at EICMA. From L to R: TVS M1-S, TVS X, TVS eFX three O, TVS RTX 300 and RTX 300 BTO, TVS Ta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
